Israel Chemotherapy-Induced Peripheral Neuropathy Market (2025-2031) | Outlook, Value, Competitive Landscape, Size & Revenue, Companies, Forecast, Analysis, Industry, Growth, Share, Trends, Segmentation

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 Israel Country Macro Economic Indicators

3.2 Israel Chemotherapy-Induced Peripheral Neuropathy Market Revenues & Volume, 2021 & 2031F

3.3 Israel Chemotherapy-Induced Peripheral Neuropathy Market - Industry Life Cycle

3.4 Israel Chemotherapy-Induced Peripheral Neuropathy Market - Porter's Five Forces

3.5 Israel Chemotherapy-Induced Peripheral Neuropathy Market Revenues & Volume Share, By Drug Class, 2021 & 2031F

3.6 Israel Chemotherapy-Induced Peripheral Neuropathy Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of cancer in Israel, leading to higher demand for chemotherapy and subsequently higher incidence of chemotherapy-induced peripheral neuropathy.

4.2.2 Technological advancements in the development of chemotherapy drugs that are more effective and have fewer side effects, driving the market for treatments of chemotherapy-induced peripheral neuropathy.

4.2.3 Growing awareness among healthcare professionals and patients about the importance of early detection and management of chemotherapy-induced peripheral neuropathy.

4.3 Market Restraints

4.3.1 High cost associated with the treatment of chemotherapy-induced peripheral neuropathy, limiting access to care for some patients.

4.3.2 Lack of standardization in the diagnosis and management of chemotherapy-induced peripheral neuropathy, leading to inconsistent treatment outcomes.

4.3.3 Potential side effects and risks associated with existing treatments for chemotherapy-induced peripheral neuropathy, leading to concerns among patients and healthcare providers.

6.1 Israel Chemotherapy-Induced Peripheral Neuropathy Market, By Drug Class

6.1.1 Overview and Analysis

6.1.2 Israel Chemotherapy-Induced Peripheral Neuropathy Market Revenues & Volume, By Drug Class, 2021- 2031F

6.1.3 Israel Chemotherapy-Induced Peripheral Neuropathy Market Revenues & Volume, By Steroids, 2021- 2031F

6.1.4 Israel Chemotherapy-Induced Peripheral Neuropathy Market Revenues & Volume, By Antidepressants, 2021- 2031F

6.1.5 Israel Chemotherapy-Induced Peripheral Neuropathy Market Revenues & Volume, By Anti-Seizure, 2021- 2031F

6.1.6 Israel Chemotherapy-Induced Peripheral Neuropathy Market Revenues & Volume, By Narcotics, 2021- 2031F

6.2 Israel Chemotherapy-Induced Peripheral Neuropathy Market, By Distribution Channel

6.2.1 Overview and Analysis

6.2.2 Israel Chemotherapy-Induced Peripheral Neuropathy Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F

6.2.3 Israel Chemotherapy-Induced Peripheral Neuropathy Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F

6.2.4 Israel Chemotherapy-Induced Peripheral Neuropathy Market Revenues & Volume, By Online Pharmacy, 2021- 2031F

7.1 Israel Chemotherapy-Induced Peripheral Neuropathy Market Export to Major Countries

7.2 Israel Chemotherapy-Induced Peripheral Neuropathy Market Imports from Major Countries

8.1 Number of clinical trials focused on developing new treatments for chemotherapy-induced peripheral neuropathy in Israel.

8.2 Percentage of oncologists in Israel incorporating guidelines for the prevention and management of chemotherapy-induced peripheral neuropathy in their practice.

8.3 Patient satisfaction rates with the quality of care and support received for chemotherapy-induced peripheral neuropathy in Israel.

9.1 Israel Chemotherapy-Induced Peripheral Neuropathy Market Opportunity Assessment, By Drug Class, 2021 & 2031F

9.2 Israel Chemotherapy-Induced Peripheral Neuropathy Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F

10.1 Israel Chemotherapy-Induced Peripheral Neuropathy Market Revenue Share, By Companies, 2024

10.2 Israel Chemotherapy-Induced Peripheral Neuropathy Market Competitive Benchmarking, By Operating and Technical Parameters